Cerity Partners’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.71M Buy
46,203
+8,020
+21% +$336K ﹤0.01% 1410
2026
Q1
$1.23M Buy
38,183
+29,106
+321% +$1.08M ﹤0.01% 1747
2025
Q4
$382K Buy
+9,077
New +$366K ﹤0.01% 2265
2025
Q3
– Sell
-23,424
Closed -$633K – 2878
2025
Q2
$633K Buy
23,424
+11,205
+92% +$325K ﹤0.01% 1748
2025
Q1
$362K Sell
12,219
-1,267
-9% -$48.3K ﹤0.01% 1926
2024
Q4
$524K Buy
13,486
+814
+6% +$30.8K ﹤0.01% 1729
2024
Q3
$431K Buy
+12,672
New +$356K ﹤0.01% 1855

Other funds holding VCYT

Cerity Partners's VCYT Position: Q2 2026 in Review

Cerity Partners increased its Veracyte (VCYT) stake by 21% in Q2 2026, buying an estimated $336K and bringing the position to 46,203 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #1410.

Cerity Partners first reported a position in VCYT in Q3 2024 and has held it in 7 quarters since. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Cerity Partners held 46,203 shares of Veracyte worth $2.71M as of Q2 2026.
  • Cerity Partners bought 8,020 Veracyte shares in Q2 2026, an estimated $336K.
  • Veracyte made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1410 holding.
  • Cerity Partners first reported a position in Veracyte in Q3 2024 and has held it in 7 quarters since.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.